{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:33:43Z","timestamp":1793036023142,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic intestinal pseudo-obstruction (CIPO) is a type of intestinal dysfunction with symptoms of intestinal blockage but without the actual mechanical obstruction. Currently, there are no drugs available to treat this disease. Herein, we report the characterization of the PrP-SCA7-92Q transgenic (Tg) line as a valuable CIPO mouse model and investigated the tolerability and efficacy of the 5-hydroxytryptamine type-4 receptor (5HT4R) agonist velusetrag as a promising pharmacological treatment for CIPO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To test the pharmacodynamics of velusetrag, 8-week-old SCA7 Tg mice, which express human mutated <jats:italic>Ataxin-7<\/jats:italic> gene containing 92 CAG repeats under the mouse prion protein promoter, were treated for 5\u00a0weeks by oral route with velusetrag at 1 and 3\u00a0mg\/kg doses or vehicle. Body weight was monitored throughout the treatment. After sacrifice, the small intestine and proximal colon were collected for whole-mount immunostaining. Untreated, age-matched, C57BL\/6J mice were also used as controls in comparison with the other experimental groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis of SCA7 Tg mice showed tissue damage and alterations, mucosal abnormalities, and ulcers in the distal small intestine and proximal colon. Morphological changes were associated with significant neuronal loss, as shown by decreased staining of pan-neuronal markers, and with accumulation of ataxin-7-positive inclusions in cholinergic neurons. Administration of velusetrag reversed intestinal abnormalities, by normalizing tissue damage and re-establishing the normal level of glia\/neuron\u2019s count in both the small and large intestines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We demonstrated that the PrP-SCA7-92Q Tg line, a model originally developed to mimic spinocerebellar ataxia, is suitable to study CIPO pathology and can be useful in establishing new therapeutic strategies, such as in the case of velusetrag. Our results suggest that velusetrag is a promising compound to treat patients affected by CIPO or intestinal dysmotility disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1411642","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:57:13Z","timestamp":1722315433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The 5HT4R agonist velusetrag efficacy on neuropathic chronic intestinal pseudo-obstruction in PrP-SCA7-92Q transgenic mice"],"prefix":"10.3389","volume":"15","author":[{"given":"Yongqiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Colla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Vesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e14523","DOI":"10.1111\/nmo.14523","article-title":"A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis","volume":"35","author":"Abell","year":"2023","journal-title":"Neurogastroenterol. Motil."},{"key":"B2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/acn3.51266","article-title":"Lower urinary tract and bowel dysfunction in spinocerebellar ataxias","volume":"8","author":"Afonso Ribeiro","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.vph.2012.11.002","article-title":"An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954","volume":"58","author":"Beattie","year":"2013","journal-title":"Vasc. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1101\/gad.186601","article-title":"The transcription factor Sox10 is a key regulator of peripheral glial development","volume":"15","author":"Britsch","year":"2001","journal-title":"Genes Dev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/brain\/123.12.2519","article-title":"Distribution of ataxin-7 in normal human brain and retina","volume":"12","author":"Cancel","year":"2000","journal-title":"Brain"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/acn3.51189","article-title":"Re-defining the clinicopathological spectrum of neuronal intranuclear inclusion disease","volume":"7","author":"Chen","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1053\/j.gastro.2007.08.043","article-title":"Visceral neuropathy and intestinal pseudo-obstruction in a murine model of a nuclear inclusion disease","volume":"133","author":"Clarke","year":"2007","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1136\/jmedgenet-2019-106268","article-title":"Long-read sequencing identified repeat expansions in the 5\u2019UTR of the NOTCH2NLC gene from Chinese patients with neuronal intranuclear inclusion disease","volume":"56","author":"Deng","year":"2019","journal-title":"J. Med. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1365-2036.2010.04456.x","article-title":"Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation \u2013 a 4-week, randomized, double-blind, placebo-controlled, dose\u2013response study","volume":"32","author":"Goldberg","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ydbio.2016.03.032","article-title":"Clinical aspects of neurointestinal disease: Pathophysiology, diagnosis, and treatment","volume":"417","author":"Goldstein","year":"2016","journal-title":"Dev. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"818757","DOI":"10.3389\/fnins.2022.818757","article-title":"The molecular Basis of Spinocerebellar Ataxia Type 7","volume":"16","author":"Goswami","year":"2022","journal-title":"Front. Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41531-023-00582-1","article-title":"Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson\u2019s disease","volume":"9","author":"Grigoletto","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/j.gastro.2011.12.041","article-title":"Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity","volume":"142","author":"Hoffman","year":"2012","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41588-019-0458-z","article-title":"Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngo-distal myopathy and an overlapping disease","volume":"51","author":"Ishiura","year":"2019","journal-title":"Nat. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-319-71779-1_9","article-title":"Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7","volume":"1049","author":"Karam","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.16344","article-title":"Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study","volume":"53","author":"Kuo","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40478-022-01383-y","article-title":"The polyG diseases: a new disease entity","volume":"10","author":"Liufu","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1016\/j.bmcl.2012.08.051","article-title":"Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation","volume":"22","author":"Long","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B19","doi-asserted-by":"publisher","first-page":"934725","DOI":"10.3389\/fnagi.2022.934725","article-title":"Clinical and mechanism advances of neuronal intranuclear inclusion disease","volume":"14","author":"Lu","year":"2002","journal-title":"Front. Aging Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s10571-016-0457-x","article-title":"Development of Calbindin- and Calretinin-Immunopositive Neurons in the Enteric Ganglia of Rats","volume":"37","author":"Masliukov","year":"2017","journal-title":"Cell. Mol. Neurobiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrgastro.2013.105","article-title":"Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets","volume":"10","author":"Mawe","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s13311-019-00778-5","article-title":"Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7","volume":"16","author":"Niewiadomska-Cimicka","year":"2019","journal-title":"Neurotherapeutics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3390\/microorganisms9122549","article-title":"Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota?","volume":"9","author":"Radocchia","year":"2021","journal-title":"Microorganisms"},{"key":"B24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00210-008-0282-y","article-title":"The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity","volume":"378","author":"Smith","year":"2008","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41588-019-0459-y","article-title":"Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease","volume":"51","author":"Sone","year":"2019","journal-title":"Nat. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41575-020-0271-2","article-title":"Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility","volume":"17","author":"Spencer","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e200057","DOI":"10.1212\/NXG.0000000000200057","article-title":"Clinical Features and Classification of Neuronal Intranuclear Inclusion Disease","volume":"9","author":"Tai","year":"2023","journal-title":"Neurol. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ajhg.2019.05.013","article-title":"Expansion of human-specific GGC repeat in neuronal intranuclear inclusion disease-related disorders","volume":"105","author":"Tian","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/jamaneurol.2014.1902","article-title":"Massive CAG repeat expansion and somatic instability in maternally transmitted infantile spinocerebellar ataxia type 7","volume":"72","author":"Trang","year":"2015","journal-title":"JAMA Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10048-014-0424-y","article-title":"A comprehensive clinical and genetic study of a large Mexican population with spinocerebellar ataxia type 7","volume":"16","author":"Vel\u00e1zquez-P\u00e9rez","year":"2015","journal-title":"Neurogenetics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MOG.0000000000000630","article-title":"Update on chronic intestinal pseudo-obstruction","volume":"36","author":"Zenzeri","year":"2020","journal-title":"Curr. Opin. Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1411642\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:57:15Z","timestamp":1722315435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1411642\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1411642"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1411642","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"article-number":"1411642"}}